Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by 2skytracker2on Feb 16, 2013 4:47pm

172 Views

Post# 21000755

RE: RE: I expect news soon

Well, thats great, at least we know the Co. still exists and in fact someone will answer the phone....it will be interesting to see where we're at as far as progress goes.It won't take much to move this SP with only 60ml shares OS, cross your fingers. Thanks for sharing info,much appreciated and GLTA. Sky

Bullboard Posts

Opawica seeks drill permits for Bazooka Gold Targets in Abitibi